Theriva Biologics Inc. (TOVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) has a cash flow conversion efficiency ratio of -0.159x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($15.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Theriva Biologics Inc. - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TOVX total liabilities for a breakdown of total debt and financial obligations.
Theriva Biologics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theriva Biologics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noida Toll Bridge Company Limited
NSE:NOIDATOLL
|
-0.628x |
|
CMX GOLD+SILVER CORP.
F:6GS
|
-4.784x |
|
Pan Asia Footwear Public Company Limited
BK:PAF
|
-0.092x |
|
Savannah Goldfields Ltd
AU:SVG
|
-0.584x |
|
FIPP S.A.
PA:FIPP
|
0.002x |
|
Pegasus Heights Bhd
KLSE:4464
|
0.018x |
|
Physitrack PLC
ST:PTRK
|
0.065x |
|
Investsmart Group Ltd
AU:INV
|
0.282x |
Annual Cash Flow Conversion Efficiency for Theriva Biologics Inc. (1993–2025)
The table below shows the annual cash flow conversion efficiency of Theriva Biologics Inc. from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see Theriva Biologics Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.38 Million | $-16.67 Million | -1.084x | -21.99% |
| 2024-12-31 | $19.07 Million | $-16.94 Million | -0.888x | -85.63% |
| 2023-12-31 | $39.70 Million | $-19.00 Million | -0.479x | -36.83% |
| 2022-12-31 | $54.56 Million | $-19.08 Million | -0.350x | -77.46% |
| 2021-12-31 | $65.41 Million | $-12.89 Million | -0.197x | +91.48% |
| 2020-12-31 | $5.26 Million | $-12.17 Million | -2.314x | -91.62% |
| 2019-12-31 | $11.49 Million | $-13.87 Million | -1.208x | -84.91% |
| 2018-12-31 | $26.45 Million | $-17.28 Million | -0.653x | -111.02% |
| 2017-12-31 | $-3.41 Million | $-20.20 Million | 5.925x | +147.76% |
| 2016-12-31 | $2.25 Million | $-27.90 Million | -12.406x | -378.60% |
| 2015-12-31 | $15.00 Million | $-38.89 Million | -2.592x | -54.06% |
| 2014-12-31 | $9.56 Million | $-16.08 Million | -1.683x | -231.99% |
| 2013-12-31 | $15.23 Million | $-7.72 Million | -0.507x | +25.94% |
| 2012-12-31 | $13.03 Million | $-8.92 Million | -0.684x | -68.03% |
| 2011-12-31 | $7.06 Million | $-2.88 Million | -0.407x | -27.86% |
| 2010-12-31 | $3.58 Million | $-1.14 Million | -0.319x | +61.32% |
| 2009-12-31 | $3.54 Million | $-2.92 Million | -0.824x | -14.83% |
| 2008-12-31 | $6.76 Million | $-4.85 Million | -0.717x | -29.68% |
| 2007-12-31 | $11.95 Million | $-6.61 Million | -0.553x | -175.54% |
| 2006-12-31 | $11.79 Million | $-2.37 Million | -0.201x | -113.06% |
| 2005-12-31 | $-703.84K | $-1.08 Million | 1.537x | +306.12% |
| 2002-12-31 | $-15.39 Million | $-5.82 Million | 0.379x | -57.36% |
| 2001-12-31 | $-9.09 Million | $-8.07 Million | 0.888x | -93.49% |
| 2000-12-31 | $-413.72K | $-5.65 Million | 13.647x | +156.73% |
| 1999-12-31 | $671.07K | $-16.14 Million | -24.056x | +9.95% |
| 1998-12-31 | $700.00K | $-18.70 Million | -26.714x | -977.19% |
| 1997-12-31 | $-2.20 Million | $-6.70 Million | 3.045x | +186.29% |
| 1996-12-31 | $1.70 Million | $-6.00 Million | -3.529x | +15.29% |
| 1995-12-31 | $1.80 Million | $-7.50 Million | -4.167x | -146.30% |
| 1994-12-31 | $-500.00K | $-4.50 Million | 9.000x | +511.43% |
| 1993-12-31 | $1.60 Million | $-3.50 Million | -2.188x | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more